| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Article |





From the Departments of Pathology and Thoracic
Surgery,*
National Defense Medical College,
Tokorozawa, Saitama, Japan; the Pathology
Section,
National Heart, Lung and Blood
Institute, National Institutes of Health, Bethesda, Maryland; and the
Department of Pulmonary and Mediastinal
Pathology,
Armed Forces Institute of
Pathology, Washington, District of Columbia
To investigate the association between the expression of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) and the clinicopathological features in lepidic and invasive components of adenocarcinoma of the lung, we performed immunostaining for type IV collagen, various MMPs, and TIMPs in 27 cases of invasive adenocarcinomas and 5 cases of atypical adenomatous hyperplasia of alveolar epithelial cells (AAH). Mean extent of lepidic growth was 61% and the survival was significantly better in cases with 50% or more lepidic component. The preservation of type IV collagen in lepidic areas correlated inversely with lymphatic or vascular invasion (P = 0.02 and 0.002, respectively). Five-year survival was reduced in cases showing destruction of type IV collagen (P = 0.004) or expression of MMP-2 (P = 0.008) in lepidic areas. MMP-2 co-localized with MT-1-MMP (its activating enzyme) and TIMP-2 in neoplastic cells. Reactivity for other MMPs and TIMPs did not correlate with destruction of type IV collagen or prognosis. Type IV collagen was preserved in all cases of AAH. MMP-2, but not MT-1-MMP, was expressed in two of the five cases of AAH. Immunostaining for type IV collagen MMP-2 is useful in evaluating the prognosis of the lung.
This article has been cited by other articles:
![]() |
Y. Miyata, T. Iwata, K. Ohba, S. Kanda, M. Nishikido, and H. Kanetake Expression of Matrix Metalloproteinase-7 on Cancer Cells and Tissue Endothelial Cells in Renal Cell Carcinoma: Prognostic Implications and Clinical Significance for Invasion and Metastasis Clin. Cancer Res., December 1, 2006; 12(23): 6998 - 7003. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Dong, M. Sato, A. Sakurada, M. Sagawa, C. Endo, S. Wu, S. Yamanaka, A. Horii, and T. Kondo Computed tomographic images reflect the biologic behavior of small lung adenocarcinoma: They correlate with cell proliferation, microvascularization, cell adhesion, degradation of extracellular matrix, and K-ras mutation J. Thorac. Cardiovasc. Surg., September 1, 2005; 130(3): 733 - 739. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ishikawa, K. Takenaka, K. Yanagihara, R. Miyahara, Y. Kawano, Y. Otake, S. Hasegawa, H. Wada, and F. Tanaka Matrix Metalloproteinase-2 Status in Stromal Fibroblasts, Not in Tumor Cells, Is a Significant Prognostic Factor in Non-Small-Cell Lung Cancer Clin. Cancer Res., October 1, 2004; 10(19): 6579 - 6585. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. S. Aljada, N. Ramnath, K. Donohue, S. Harvey, J. J. Brooks, S. M. Wiseman, T. Khoury, G. Loewen, H. K. Slocum, T. M. Anderson, et al. Upregulation of the Tissue Inhibitor of Metalloproteinase-1 Protein Is Associated With Progression of Human Non-Small-Cell Lung Cancer J. Clin. Oncol., August 15, 2004; 22(16): 3218 - 3229. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Pinto, P. E. d. O. Carvalho, L. Antonangelo, A. Garippo, A. G. P. da Silva, F. Soares, R. Younes, R. Beyruti, T. Takagaki, P. Saldiva, et al. Morphometric Evaluation of Tumor Matrix Metalloproteinase 9 Predicts Survival after Surgical Resection of Adenocarcinoma of the Lung Clin. Cancer Res., August 1, 2003; 9(8): 3098 - 3104. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Noda, S. Ishida, M. Inoue, K.-i. Obata, Y. Oguchi, Y. Okada, and E. Ikeda Production and Activation of Matrix Metalloproteinase-2 in Proliferative Diabetic Retinopathy Invest. Ophthalmol. Vis. Sci., May 1, 2003; 44(5): 2163 - 2170. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y Hakoda, Y Ito, A Nagate, K Minemura, K Utsumi, M Aoshima, and K Ohyashiki Increased collagenase activity in macrophages from bronchial lavage as a diagnostic marker of non-small cell lung cancer Thorax, February 1, 2003; 58(2): 122 - 126. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |